Olaparib in the management of ovarian cancer
Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) poly...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538690/ |
| id |
pubmed-4538690 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-45386902015-08-25 Olaparib in the management of ovarian cancer Bixel, Kristin Hays, John L Review Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. This review article will provide an overview of the BRCA genes and homologous recombination, the role of PARP in DNA repair and the biological rationale for the use of PARP inhibitors as cancer therapy, and ultimately will focus on the use of olaparib in the management of ovarian cancer. Dove Medical Press 2015-08-07 /pmc/articles/PMC4538690/ /pubmed/26309417 http://dx.doi.org/10.2147/PGPM.S62809 Text en © 2015 Bixel and Hays. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Bixel, Kristin Hays, John L |
| spellingShingle |
Bixel, Kristin Hays, John L Olaparib in the management of ovarian cancer |
| author_facet |
Bixel, Kristin Hays, John L |
| author_sort |
Bixel, Kristin |
| title |
Olaparib in the management of ovarian cancer |
| title_short |
Olaparib in the management of ovarian cancer |
| title_full |
Olaparib in the management of ovarian cancer |
| title_fullStr |
Olaparib in the management of ovarian cancer |
| title_full_unstemmed |
Olaparib in the management of ovarian cancer |
| title_sort |
olaparib in the management of ovarian cancer |
| description |
Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. This review article will provide an overview of the BRCA genes and homologous recombination, the role of PARP in DNA repair and the biological rationale for the use of PARP inhibitors as cancer therapy, and ultimately will focus on the use of olaparib in the management of ovarian cancer. |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538690/ |
| _version_ |
1613260349290577920 |